Shire Plc Ads (SHPG) 176.48 $SHPG
Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA(R) (adalimumab) Biosimilar, at EULAR 2016
GlobeNewswire - Wed Jun 08, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company's lead biosimilar candidate developed in collaboration with Baxalta, now part of Shire plc, will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London.
SHPG: 176.47 (-7.48), MNTA: 11.75 (-0.05)
Shire to Participate at Two Upcoming Investor Conferences
PR Newswire Europe - Fri Jun 03, 7:01AM CDT
LEXINGTON, Massachusetts, June 3, 2016 /PRNewswire/ --
SHPG: 176.47 (-7.48)
Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions
PR Newswire Europe - Fri Jun 03, 2:41AM CDT
DUBLIN, June 3, 2016 /PRNewswire/ --
SHPG: 176.47 (-7.48), BXLT: 46.02 (-0.18)
5 Top ROE Stocks to Profit in Turbulent Times
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 10:58AM CDT
ROE helps investors distinguish between profit-generating companies from profit burners.
BAK: 11.46 (-0.32), EA: 75.63 (-0.62), SHPG: 176.47 (-7.48), MO: 65.92 (+0.06), LEA: 115.92 (-1.81)
Shire (SHPG) Gets Favorable CHMP Opinion for Revestive
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:30AM CDT
Shire plc (SHPG) announced that the CHMP has granted a positive opinion for the label expansion of Revestive (teduglutide) 5 mg powder for injection in pediatric patients (aged 1 to 17 years) suffering from short bowel syndrome.
SHPG: 176.47 (-7.48), PFE: 35.36 (+0.05), BXLT: 46.02 (-0.18), BMY: 72.76 (+0.03)
TransDigm Group Set to Join the S&P 500; Helen of Troy and Brocade Communications Systems to Join S&P MidCap 400; Team and MDC Holdings to Join S&P SmallCap 600
PR Newswire - Fri May 27, 4:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
HELE: 104.16 (-1.14), SPGI: 107.65 (-2.39), TISI: 28.14 (-0.74), BIN.TO: 41.40 (-0.68), MDC: 24.12 (-0.43), SHPG: 176.47 (-7.48), TDG: 261.90 (-4.33), WCN: 73.34 (+0.55), BIN: 31.61 (-1.16), BXLT: 46.02 (-0.18), RKUS: 12.87 (+0.15), BRCD: 8.89 (-0.08)
CORRECTING and REPLACING Baxalta Shareholders Vote to Approve Combination
BusinessWire - Fri May 27, 9:00AM CDT
First paragraph, second sentence of release should read: Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 76.9 percent of shares outstanding cast in favor of the proposal, which represents approximately 98.9 percent of the votes cast at the meeting (instead of Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 98.9 percent of shares outstanding cast in favor of the proposal).
SHPG: 176.47 (-7.48), BXLT: 46.02 (-0.18)
Baxalta Shareholders Vote to Approve Combination
BusinessWire - Fri May 27, 8:00AM CDT
Baxalta Incorporated (NYSE:BXLT) today announced the results of a vote on the proposals identified in the definitive proxy statement/prospectus, dated April 18, 2016, at a special meeting of shareholders held earlier this morning relating to the proposed combination with Shire plc (LSE: SHP, NASDAQ: SHPG). Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 98.9 percent of shares outstanding cast in favor of the proposal.
SHPG: 176.47 (-7.48), BXLT: 46.02 (-0.18)
Shire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide) for Paediatric Patients with Short Bowel Syndrome
PR Newswire Europe - Fri May 27, 1:01AM CDT
ZUG, Switzerland, May 27, 2016 /PRNewswire/ --
SHPG: 176.47 (-7.48)
Baxalta Reports Positive Phase I Study Data on BAX 930
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:56PM CDT
Baxalta Incorporated (BXLT) reported positive phase I study data on BAX 930 for the treatment of severe hereditary thrombotic thrombocytopenic purpura.
ANIP: 52.64 (-1.05), SHPG: 176.47 (-7.48), RTRX: 17.54 (-0.16), BXLT: 46.02 (-0.18)
Baxalta Announces Preliminary Merger Consideration Election Results
BusinessWire - Mon May 23, 7:00AM CDT
Baxalta Incorporated (NYSE:BXLT) today announced the preliminary results of the elections made by its stockholders as to the form of stock consideration to be received in Baxalta's merger with Shire plc (LSE: SHP, NASDAQ: SHPG).
SHPG: 176.47 (-7.48), BXLT: 46.02 (-0.18)
5 Foreign Stocks Worth Investing Post-Q1 Earnings
Zacks Equity Research - Zacks Investment Research - Tue May 17, 4:04PM CDT
Amid the weak market conditions, you must be thinking of avoiding stock investing as much as possible. But it will be a good idea to diversify your portfolio by adding a few foreign stocks.
KEP: 26.26 (+0.04), DEG: 26.05 (-0.70), MFC: 14.16 (-0.43), SHPG: 176.47 (-7.48), SBS: 8.14 (-0.16)
Catalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 2:29PM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 7 cents per share in the first quarter of 2016, which was wider than the year-ago loss of 6 cents but in line with the Zacks Consensus Estimate.
ABT: 38.37 (-0.50), CPRX: 0.62 (-0.03), SHPG: 176.47 (-7.48), ARQL: 1.82 (+0.04)
Shire to Present New Research at 2016 American Psychiatric Association Annual Meeting
PR Newswire - Wed May 11, 2:00PM CDT
For US Audiences Only - Shire plc (LSE: SHP, NASDAQ: SHPG) will present new research on Binge Eating Disorder (B.E.D.) and Attention-Deficit/Hyperactivity Disorder (ADHD) at the upcoming 169th Annual Meeting of the American Psychiatric Association (APA) in Atlanta, GA, demonstrating its ongoing commitment to furthering the understanding and management of psychiatric disorders.
SHPG: 176.47 (-7.48)
Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss
Ekta Bagri - Zacks Investment Research - Tue May 10, 1:29PM CDT
Epizyme, Inc. (EPZM) reported a loss of 41 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of a loss of 47 cents and the year-ago loss of $1.75.
SHPG: 176.47 (-7.48), EPZM: 11.95 (-0.31), GSK: 41.08 (-0.98), CELG: 103.22 (-2.91)
Avalanche (AAVL) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:16AM CDT
Avalanche Biotechnologies, Inc. (AAVL) reported a loss of 57 cents per share in the first quarter of 2016,.
SHPG: 176.47 (-7.48), AAVL: 4.14 (-0.18), NKTR: 16.01 (-0.27), REGN: 371.75 (-9.33)
Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Lag
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:59PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.33 per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.58 but wider than the year-ago loss of $1.78.
SHPG: 176.47 (-7.48), ICPT: 151.08 (-3.14), BIOD: 0.34 (unch), NKTR: 16.01 (-0.27)
Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA(R) (adalimumab) Biosimilar, at EULAR 2016
GlobeNewswire - Wed Jun 08, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company's lead biosimilar candidate developed in collaboration with Baxalta, now part of Shire plc, will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London.
SHPG: 176.47 (-7.48), MNTA: 11.75 (-0.05)
Shire to Participate at Two Upcoming Investor Conferences
PR Newswire Europe - Fri Jun 03, 7:01AM CDT
LEXINGTON, Massachusetts, June 3, 2016 /PRNewswire/ --
SHPG: 176.47 (-7.48)
Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions
PR Newswire Europe - Fri Jun 03, 2:41AM CDT
DUBLIN, June 3, 2016 /PRNewswire/ --
SHPG: 176.47 (-7.48), BXLT: 46.02 (-0.18)
5 Top ROE Stocks to Profit in Turbulent Times
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 10:58AM CDT
ROE helps investors distinguish between profit-generating companies from profit burners.
BAK: 11.46 (-0.32), EA: 75.63 (-0.62), SHPG: 176.47 (-7.48), MO: 65.92 (+0.06), LEA: 115.92 (-1.81)
Shire (SHPG) Gets Favorable CHMP Opinion for Revestive
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:30AM CDT
Shire plc (SHPG) announced that the CHMP has granted a positive opinion for the label expansion of Revestive (teduglutide) 5 mg powder for injection in pediatric patients (aged 1 to 17 years) suffering from short bowel syndrome.
SHPG: 176.47 (-7.48), PFE: 35.36 (+0.05), BXLT: 46.02 (-0.18), BMY: 72.76 (+0.03)
TransDigm Group Set to Join the S&P 500; Helen of Troy and Brocade Communications Systems to Join S&P MidCap 400; Team and MDC Holdings to Join S&P SmallCap 600
PR Newswire - Fri May 27, 4:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
HELE: 104.16 (-1.14), SPGI: 107.65 (-2.39), TISI: 28.14 (-0.74), BIN.TO: 41.40 (-0.68), MDC: 24.12 (-0.43), SHPG: 176.47 (-7.48), TDG: 261.90 (-4.33), WCN: 73.34 (+0.55), BIN: 31.61 (-1.16), BXLT: 46.02 (-0.18), RKUS: 12.87 (+0.15), BRCD: 8.89 (-0.08)
CORRECTING and REPLACING Baxalta Shareholders Vote to Approve Combination
BusinessWire - Fri May 27, 9:00AM CDT
First paragraph, second sentence of release should read: Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 76.9 percent of shares outstanding cast in favor of the proposal, which represents approximately 98.9 percent of the votes cast at the meeting (instead of Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 98.9 percent of shares outstanding cast in favor of the proposal).
SHPG: 176.47 (-7.48), BXLT: 46.02 (-0.18)
Baxalta Shareholders Vote to Approve Combination
BusinessWire - Fri May 27, 8:00AM CDT
Baxalta Incorporated (NYSE:BXLT) today announced the results of a vote on the proposals identified in the definitive proxy statement/prospectus, dated April 18, 2016, at a special meeting of shareholders held earlier this morning relating to the proposed combination with Shire plc (LSE: SHP, NASDAQ: SHPG). Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 98.9 percent of shares outstanding cast in favor of the proposal.
SHPG: 176.47 (-7.48), BXLT: 46.02 (-0.18)
Shire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide) for Paediatric Patients with Short Bowel Syndrome
PR Newswire Europe - Fri May 27, 1:01AM CDT
ZUG, Switzerland, May 27, 2016 /PRNewswire/ --
SHPG: 176.47 (-7.48)
Baxalta Reports Positive Phase I Study Data on BAX 930
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:56PM CDT
Baxalta Incorporated (BXLT) reported positive phase I study data on BAX 930 for the treatment of severe hereditary thrombotic thrombocytopenic purpura.
ANIP: 52.64 (-1.05), SHPG: 176.47 (-7.48), RTRX: 17.54 (-0.16), BXLT: 46.02 (-0.18)
Baxalta Announces Preliminary Merger Consideration Election Results
BusinessWire - Mon May 23, 7:00AM CDT
Baxalta Incorporated (NYSE:BXLT) today announced the preliminary results of the elections made by its stockholders as to the form of stock consideration to be received in Baxalta's merger with Shire plc (LSE: SHP, NASDAQ: SHPG).
SHPG: 176.47 (-7.48), BXLT: 46.02 (-0.18)
5 Foreign Stocks Worth Investing Post-Q1 Earnings
Zacks Equity Research - Zacks Investment Research - Tue May 17, 4:04PM CDT
Amid the weak market conditions, you must be thinking of avoiding stock investing as much as possible. But it will be a good idea to diversify your portfolio by adding a few foreign stocks.
KEP: 26.26 (+0.04), DEG: 26.05 (-0.70), MFC: 14.16 (-0.43), SHPG: 176.47 (-7.48), SBS: 8.14 (-0.16)
Catalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 2:29PM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 7 cents per share in the first quarter of 2016, which was wider than the year-ago loss of 6 cents but in line with the Zacks Consensus Estimate.
ABT: 38.37 (-0.50), CPRX: 0.62 (-0.03), SHPG: 176.47 (-7.48), ARQL: 1.82 (+0.04)
Shire to Present New Research at 2016 American Psychiatric Association Annual Meeting
PR Newswire - Wed May 11, 2:00PM CDT
For US Audiences Only - Shire plc (LSE: SHP, NASDAQ: SHPG) will present new research on Binge Eating Disorder (B.E.D.) and Attention-Deficit/Hyperactivity Disorder (ADHD) at the upcoming 169th Annual Meeting of the American Psychiatric Association (APA) in Atlanta, GA, demonstrating its ongoing commitment to furthering the understanding and management of psychiatric disorders.
SHPG: 176.47 (-7.48)
Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss
Ekta Bagri - Zacks Investment Research - Tue May 10, 1:29PM CDT
Epizyme, Inc. (EPZM) reported a loss of 41 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of a loss of 47 cents and the year-ago loss of $1.75.
SHPG: 176.47 (-7.48), EPZM: 11.95 (-0.31), GSK: 41.08 (-0.98), CELG: 103.22 (-2.91)
Avalanche (AAVL) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:16AM CDT
Avalanche Biotechnologies, Inc. (AAVL) reported a loss of 57 cents per share in the first quarter of 2016,.
SHPG: 176.47 (-7.48), AAVL: 4.14 (-0.18), NKTR: 16.01 (-0.27), REGN: 371.75 (-9.33)
Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Lag
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:59PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.33 per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.58 but wider than the year-ago loss of $1.78.
SHPG: 176.47 (-7.48), ICPT: 151.08 (-3.14), BIOD: 0.34 (unch), NKTR: 16.01 (-0.27)
